An updated patent review of isoflavones and isocoumarins (2018–2024)

ABSTRACT Introduction It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018–2024 isocoumarins and isoflavones chemistry has attracted attention due to their biological and pharmaceutical properties. Areas covered This review focuses on patents relating to the therapeutic properties of isocoumarins and isoflavones between 2018 and 2024. The latest patented studies of isocoumarin and isoflavone are summarized by using the keywords ‘isocoumarin’ and ‘isoflavone’ in SciFinder, PubMed, and Google Patents databases in the year from 2018 to 2024. Expert opinion A wide range of important pharmaceutical properties are exhibited by isocoumarins and isoflavones and their synthetic analogs. In addition, isocoumarins and isoflavones have the potential to couple with other biologically active molecules, synergistically enhancing delivery and biological effects. In addition, scientists should direct their efforts toward the synthesis of halo-substituted and functionalized heterocyclic ring derivatives of isocoumarins and isoflavones, with a view to obtaining lead compounds. The lack of pharmacology and pharmacokinetics data along with in vivo studies for isocoumarins and isoflavones, prevents effective regulatory decisions from being proposed. In addition, detailed efficacy studies in well-established disease models are required to determine the clinical effects of isocoumarins and isoflavones.